CTI and Discovery Capital back PHEMI

By Iris Dorbian — 6 months ago

Vancouver, British Columbia-based PHEMI, a big data warehouse company, has secured C$12.2 million in funding. CTI Life Sciences Fund and British Columbia Discovery Fund led the round with participation from other investors that included BDC Capital Healthcare Venture Fund and Yaletown Venture Partners.

Continue

Xagenic Appoints Two Board Members

By Angela Sormani — 3 years ago

Xagenic, a point-of-care molecular diagnostics company, has appointed Bruce A. Cohen as executive chairman of the board. R. Erik Holmlin has also been appointed to the board of directors. Xagenic is backed by CTI Life Sciences Fund, the Ontario Emerging Technologies Fund and QIAGEN. PRESS RELEASE Xagenic Inc., a privately held point-of-care molecular diagnostics company, […]

Continue

Xagenic Seals $10M Series A

4 years ago

Xagenic Inc., a molecular diagnostics company spun out of the University of Toronto, has raised $10 million in Series A financing co-led by CTI Life Sciences Fund and the Ontario Emerging Technologies Fund. QIAGEN N.V. also participated in the round. Toronto-based Xagenic will use the funds to continue development of its technology for decentralized, rapid diagnostic testing.

Continue

Alexion Pharmaceuticals Buys Enobia Pharma

4 years ago

Alexion Pharmaceuticals Inc. will pay $610 million in cash – and as much as $470 million in future milestone-based payments – to acquire Enobia Pharma Corp. Enobia is a biopharma company developing therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders. Enobia closed a $40 million round earlier this year, and was backed by investors including OrbiMed Advisors, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners.

Continue

Zymeworks Inks $8.1M

4 years ago

Vancouver-based Zymeworks Inc., a biotech company focused on protein-based therapeutics, has raised a total of $8.1 million. CTI Life Sciences Fund and Advanced Biotechnologies Venture Fund are among the investors. The money will be used for continued development.

Continue

Enobia Pharma Closes on $40M

4 years ago

Enobia Pharma Inc., a Montreal-based biotech company developing therapeutics for bone disorders, has closed a $40 million round. The company’s backers include OrbiMed Advisors, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners. BofA Merrill Lynch acted as the exclusive placement agent to the company.

Continue